Why the study?
Does aspirin alter human LDL and affect its catabolism by fibroblasts and macrophages in vitro?
Does aspirin alter human LDL and affect its catabolism by fibroblasts and macrophages in vitro?
In vitro aspirin treatment alters human LDL and reduces its recognition by fibroblast apo B/E receptors, suggesting a potential mechanism by which long-term aspirin could influence the LDL-receptor pathway.
Answers are grounded in this paper and cite their sources.
In vitro aspirin modification of LDL may impair receptor recognition; hypothesis-generating for in vivo catabolism with no clinical implications yet.
Aspirin interacts in vitro with human low-density lipoprotein (LDL), which results in a decrease in free amino groups of apolipoprotein B and an increase of electrophoretic mobility of the particle. The aspirin-treated LDL was less efficiently recognized than native LDL by the apo B/E receptor of fibroblasts. These results suggest that aspirin in long-term treatment could influence the LDL-receptor pathway. However, aspirin-treated LDL did not bind to the scavenger receptor of macrophages.
No takes yet. Share an insight, caveat, or question.
Mazière et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: